Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) was the target of a significant decrease in short interest in October. As of October 15th, there was short interest totaling 96 shares, a decrease of 73.7% from the September 30th total of 365 shares. Based on an average daily trading volume, of 2 shares, the days-to-cover ratio is presently 48.0 days. Approximately 0.0% of the shares of the stock are short sold.
Basilea Pharmaceutica Price Performance
Shares of OTCMKTS BPMUF opened at $76.25 on Thursday. The firm has a 50-day simple moving average of $76.96 and a 200-day simple moving average of $69.49. The company has a current ratio of 6.60, a quick ratio of 5.97 and a debt-to-equity ratio of 0.44. Basilea Pharmaceutica has a 52 week low of $59.29 and a 52 week high of $77.40.
Basilea Pharmaceutica Company Profile
Basilea Pharmaceutica AG is a Switzerland-based biopharmaceutical company focused on discovering, developing and commercializing medicines for serious bacterial and fungal infections, as well as selected oncology indications. The company is headquartered in Basel and was established in 2000 as a spin-off from Roche.
Basilea’s principal products include Cresemba (isavuconazole), an antifungal medicine used to treat invasive fungal infections, and Zevtera (ceftobiprole), a cephalosporin antibiotic developed for several serious bacterial infections.
Further Reading
- Five stocks we like better than Basilea Pharmaceutica
- Garmin Raises Its Profit Outlook—Can the Stock Reach New Highs?
- Why Rising Rates Could Break the Bull Market Before AI Spending Can Save It
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
